Skip to main content

Caliper to Use SRU's BIND Platform

NEW YORK (GenomeWeb News) – Caliper Life Sciences will use SRU Biosystems' screening platform to offer new functional assays through its Discovery and Alliances services, SRU said today.

Under the agreement, Caliper will use SRU's label-free BIND technology for high-throughput screening and profiling for cell-based and biochemical assays.

The BIND platform can be used to access new hits and lead molecules, including compounds that undergo G-protein switching, non-G coupled pathways, and receptor desensitization, as well as inverse and partial agonists. The technology also can be used for receptor profiling on native cells, SRU said.

Caliper plans to incorporate SRU's platform in contract services it offers to the biotechnology and pharmaceutical research communities.

Financial terms of the agreement were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.